AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17684221 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain intake
Number of subjects: 28926
Study 17684221 — intervention group
Group type: COMPARATOR
Intervention: Refined-grain intake
Number of subjects: 28926
Study 15892781 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized visual-auditory correlations (video of the talker's face synchronized with the target passage)
Number of subjects: 116
Study 15892781 — intervention group
Group type: COMPARATOR
Intervention: Unsynchronized visual-auditory correlations (unsynchronized face)
Number of subjects: 116
Study 15892781 — intervention group
Group type: COMPARATOR
Intervention: Static visual-auditory correlations (static face)
Number of subjects: 116
Study 15892781 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized visual-auditory correlations (synchronized oscilloscope pattern)
Number of subjects: 116
Study 12439223 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion (300 mg/day for 10 weeks)
Number of subjects: 426
Study 12439223 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 426
Study 9579500 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine (4 microg/kg)
Number of subjects: 120
Study 9579500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 9579500 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine (4 microg/kg) with glucose-free solution
Number of subjects: 120
Study 9579500 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of 2% glucose with clonidine
Number of subjects: 120
Study 7650232 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (50 mg every 8 hours for 10 days)
Number of subjects: 18
Study 7650232 — intervention group
Group type: COMPARATOR
Intervention: Placebo (double‐blind)
Number of subjects: 18
Study 7650232 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg single dose on day 5)
Number of subjects: 18
Study 7650232 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 18
Study 2669089 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine 15 mg b.d.
Number of subjects: 822
Study 2669089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 822
Study 975730 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole (1 gm intravenous)
Number of subjects: 32
Study 975730 — intervention group
Group type: COMPARATOR
Intervention: Cephalothin (1 gm intravenous)
Number of subjects: 32
Study 975730 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole (1 gm intramuscularly)
Number of subjects: 32
Study 975730 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole (2 gm intravenously every 6 hr)
Number of subjects: 32
Study 975730 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole (2 gm loading followed by 2 gm every 6 hr)
Number of subjects: 32
Study 975730 — intervention group
Group type: COMPARATOR
Intervention: Cephalothin (2 gm loading followed by 2 gm every 6 hr)
Number of subjects: 32
Study 975730 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole and Cephalothin (both drugs)
Number of subjects: 32
Study 31532576 — intervention group
Group type: EXPERIMENTAL
Intervention: V0034CR emollient
Number of subjects: 51
Study 31532576 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 51
Study 31532576 — intervention group
Group type: COMPARATOR
Intervention: Vehicle + glycerol
Number of subjects: 51
Study 31532576 — intervention group
Group type: COMPARATOR
Intervention: Vehicle + petrolatum
Number of subjects: 51
Study 30867034 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg/day for 1 year
Number of subjects: 2840
Study 30867034 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 year
Number of subjects: 2840
Study 27996097 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection-preventive technique including povidone-iodine, double gloving, meticulous aseptic/antiseptic measures, and antibiotic prophylaxis.
Number of subjects: 762
Study 27996097 — intervention group
Group type: EXPERIMENTAL
Intervention: New pacemaker implantation
Number of subjects: 762
Study 27996097 — intervention group
Group type: EXPERIMENTAL
Intervention: New ICD implantation
Number of subjects: 762
Study 25037727 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypectomy during both insertion and withdrawal phases (study arm)
Number of subjects: 610
Study 25037727 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal phase only (control arm)
Number of subjects: 610
Study 24139127 — intervention group
Group type: EXPERIMENTAL
Intervention: Higenamine-based dietary supplement (including caffeine 270 mg and yohimbe bark extract)
Number of subjects: 16
Study 24139127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 21389299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (c‐tDCS) of left primary motor cortex (M1)
Number of subjects: 0
Study 21389299 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study 21389299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (c‐tDCS)
Number of subjects: 0
Study 21389299 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonconditioned left BB MEPs
Number of subjects: 0
Study 21389299 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral silent period of left BB
Number of subjects: 0
Study 19700776 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Number of subjects: 50
Study 19700776 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 50
Study 17605774 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mug via HandiHaler
Number of subjects: 374
Study 17605774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study 15738750 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg modafinil
Number of subjects: 60
Study 15738750 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg modafinil
Number of subjects: 60
Study 15738750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12225474 — intervention group
Group type: EXPERIMENTAL
Intervention: FID EPI sequence
Number of subjects: 60
Study 12225474 — intervention group
Group type: COMPARATOR
Intervention: SE EPI sequence
Number of subjects: 60
Study 9427706 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP) infusion at stepwise doses of 0.7, 7.0, and 70 ng/min
Number of subjects: 15
Study 9427706 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant-rate DDAVP infusion at 70 ng/min for 20 minutes
Number of subjects: 15
Study 9427706 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP) infusion at doses of 0.5, 2.5, and 10 micrograms/min
Number of subjects: 15
Study 9427706 — intervention group
Group type: COMPARATOR
Intervention: Control arm (dominant arm) during constant-rate DDAVP infusion
Number of subjects: 15
Study 8089668 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (1.5 g twice daily)
Number of subjects: 45
Study 8089668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 2682901 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride
Number of subjects: 170
Study 2682901 — intervention group
Group type: COMPARATOR
Intervention: Tryptizol
Number of subjects: 170
Study 30596581 — intervention group
Group type: EXPERIMENTAL
Intervention: Anode HD-tDCS
Number of subjects: 11
Study 30596581 — intervention group
Group type: COMPARATOR
Intervention: Cathode HD-tDCS
Number of subjects: 11
Study 30596581 — intervention group
Group type: COMPARATOR
Intervention: Sham HD-tDCS
Number of subjects: 11
Study 27112096 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of treatment by a specialist physiotherapist
Number of subjects: 30
Study 27112096 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 30
Study 25338188 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural context (visual feedback of hand)
Number of subjects: 40
Study 25338188 — intervention group
Group type: COMPARATOR
Intervention: Virtual context (computer-generated feedback)
Number of subjects: 40
Study 25338188 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent feedback
Number of subjects: 40
Study 25338188 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminal feedback
Number of subjects: 40
Study 24121753 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 491
Study 24121753 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 491
Study 24121753 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine and Zidovudine
Number of subjects: 491
Study 22171868 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacoustic musical composition
Number of subjects: 170
Study 22171868 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio field recordings
Number of subjects: 170
Study 22171868 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio field recordings with embedded binaural beats
Number of subjects: 170
Study 22171868 — intervention group
Group type: COMPARATOR
Intervention: Simulated ED ambient noise
Number of subjects: 170
Study 22171868 — intervention group
Group type: COMPARATOR
Intervention: Headphones only (control group)
Number of subjects: 170
Study 19192344 — intervention group
Group type: EXPERIMENTAL
Intervention: Visualization of meiotic spindle
Number of subjects: 10
Study 19192344 — intervention group
Group type: COMPARATOR
Intervention: No visualization of meiotic spindle
Number of subjects: 10
Study 16510658 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Start program of home visitation
Number of subjects: 443
Study 16510658 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Early Start program)
Number of subjects: 443
Study 14631087 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (33±1 degrees C for 24 hours)
Number of subjects: 70
Study 14631087 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 70
Study 14631087 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 70
Study 12006146 — intervention group
Group type: EXPERIMENTAL
Intervention: Diskus/Accuhaler
Number of subjects: 169
Study 12006146 — intervention group
Group type: COMPARATOR
Intervention: Turbuhaler
Number of subjects: 169
Study 9596366 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion of ventilation tubes (VT)
Number of subjects: 64
Study 9596366 — intervention group
Group type: COMPARATOR
Intervention: Healthy children with no history of middle ear diseases (Control)
Number of subjects: 64
Study 7646915 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal or chemotherapy
Number of subjects: 27
Study 7646915 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio/chemotherapy
Number of subjects: 27
Study 7646915 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 27
Study 2095312 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% hydrogen peroxide mouthrinse
Number of subjects: 0
Study 2095312 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 0
Study 346356 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 5 mg (single oral dose)
Number of subjects: 20
Study 346356 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (conventional therapeutic dose by inhalation)
Number of subjects: 20
Study 346356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30708998 — intervention group
Group type: EXPERIMENTAL
Intervention: Dat-e Adolescence prevention program
Number of subjects: 1423
Study 30708998 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1423
Study 28787738 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual‐based low‐level psychological intervention
Number of subjects: 119
Study 28787738 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (weight loss treatment)
Number of subjects: 119
Study 25702059 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary alpha-linolenic acid (ALA) intake
Number of subjects: 1009
Study 23600983 — intervention group
Group type: EXPERIMENTAL
Intervention: Cevimeline 30 mg three times a day for four weeks
Number of subjects: 15
Study 23600983 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine 5 mg three times a day for four weeks
Number of subjects: 15
Study 21652750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 240
Study 21652750 — intervention group
Group type: COMPARATOR
Intervention: Salicylic acid
Number of subjects: 240
Study 19405969 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Treatment (HIT)
Number of subjects: 300
Study 19405969 — intervention group
Group type: COMPARATOR
Intervention: Low Intensity Treatment (LIT)
Number of subjects: 300
Study 16931871 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine pre-treatment
Number of subjects: 13
Study 15303766 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg isosorbide dinitrate (sustained-release)
Number of subjects: 11
Study 15303766 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 11
Study 11386765 — intervention group
Group type: EXPERIMENTAL
Intervention: Acutrak screw fixation
Number of subjects: 53
Study 11386765 — intervention group
Group type: COMPARATOR
Intervention: Cast immobilisation
Number of subjects: 53
Study 9422292 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg
Number of subjects: 439
Study 9422292 — intervention group
Group type: EXPERIMENTAL
Intervention: droperidol 1.25 mg
Number of subjects: 439
Study 9422292 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 439
Study 8373715 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic hydroxychloroquine
Number of subjects: 8
Study 31970477 — intervention group
Group type: EXPERIMENTAL
Intervention: Minodronate (50 mg/4 weeks) plus alfacalcidol (1 μg/day)
Number of subjects: 152
Study 31970477 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol (1 μg/day)
Number of subjects: 152
Study 31970477 — intervention group
Group type: EXPERIMENTAL
Intervention: Minodronate plus alfacalcidol
Number of subjects: 152
Study 31970477 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol alone
Number of subjects: 152
Study 31970477 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (M and A)
Number of subjects: 152
Study 29549822 — intervention group
Group type: EXPERIMENTAL
Intervention: Social behavioral change communication intervention designed to prevent IPV
Number of subjects: 1435
Study 29549822 — intervention group
Group type: EXPERIMENTAL
Intervention: Ward-level PVNS scores
Number of subjects: 1435
Study 27473346 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting methylphenidate (OROS-MPH) prescribed to 38 patients
Number of subjects: 70
Study 27473346 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine prescribed to 32 patients
Number of subjects: 70
Study 27473346 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 70
Study 27473346 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperactive/impulsive subtype
Number of subjects: 70
Study 27473346 — intervention group
Group type: EXPERIMENTAL
Intervention: Inattentive subtype
Number of subjects: 70
Study 24809737 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein (PV) antral isolation
Number of subjects: 57
Study 23060624 — intervention group
Group type: EXPERIMENTAL
Intervention: NVA237 50 μg
Number of subjects: 1066
Study 23060624 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg
Number of subjects: 1066
Study 23060624 — intervention group
Group type: COMPARATOR
Intervention: NVA237
Number of subjects: 1066
Study 20071096 — intervention group
Group type: EXPERIMENTAL
Intervention: Socially evaluated cold pressor test
Number of subjects: 0
Study 20071096 — intervention group
Group type: COMPARATOR
Intervention: Control procedure
Number of subjects: 0
Study 18666494 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide with no desensitizers
Number of subjects: 0
Study 18666494 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide with 3% potassium nitrate
Number of subjects: 0
Study 18666494 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide with 0.5% potassium nitrate
Number of subjects: 0
Study 18666494 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide with 0.5% potassium nitrate and 0.25% sodium fluoride
Number of subjects: 0
Study 18666494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18666494 — intervention group
Group type: EXPERIMENTAL
Intervention: All active bleaching agents (including 10% carbamide peroxide with potassium nitrate)
Number of subjects: 0
Study 16129870 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient decision aid (self-administered booklet and audiotape tailored to personal stroke risk profile)
Number of subjects: 434
Study 16129870 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 434
Study 16129870 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient decision aid
Number of subjects: 434
Study 12898043 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA/dimenhydrinate (Group TD)
Number of subjects: 110
Study 12898043 — intervention group
Group type: COMPARATOR
Intervention: Volatile/dimenhydrinate (Group VD)
Number of subjects: 110
Study 12898043 — intervention group
Group type: COMPARATOR
Intervention: Volatile anaesthesia
Number of subjects: 110
Study 10786195 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan 1.5 mg/m2 on 5 consecutive days every 3 weeks
Number of subjects: 139
Study 10786195 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of topotecan 0.3 to 0.5 mg/m2
Number of subjects: 139
Study 10786195 — intervention group
Group type: COMPARATOR
Intervention: Topotecan 1.5 mg/m2/day for 5 consecutive days every 21 days
Number of subjects: 139
Study 10786195 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan
Number of subjects: 139
Study 8682118 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 3411
Study 1997045 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 7 micrograms kg‐1 i.v. infusion over 120 min
Number of subjects: 29
Study 1997045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 6386760 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy with misonidazole (12 g/m2 daily in 1.2 g/m2 fractions)
Number of subjects: 52
Study 6386760 — intervention group
Group type: COMPARATOR
Intervention: Hyperfractionated radiotherapy without misonidazole
Number of subjects: 52
Study 31767595 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative and stepped care model
Number of subjects: 570
Study 31767595 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 570
Study 29947751 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 2199
Study 29947751 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin/warfarin
Number of subjects: 2199
Study 27018693 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block with general anesthesia
Number of subjects: 74
Study 27018693 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 74
Study 24219336 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Group B)
Number of subjects: 40
Study 24219336 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (Group A)
Number of subjects: 40
Study 21837746 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hepatic inflow occlusion (IHIO) during donor hepatectomy
Number of subjects: 50
Study 21837746 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IHIO)
Number of subjects: 50
Study 21837746 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hepatic inflow occlusion (IHIO)
Number of subjects: 50
Study 19411388 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxcinod 750 mg once daily (qd)
Number of subjects: 543
Study 19411388 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxcinod 750 mg twice daily (bid)
Number of subjects: 543
Study 19411388 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxcinod 1125 mg bid
Number of subjects: 543
Study 19411388 — intervention group
Group type: EXPERIMENTAL
Intervention: rofecoxib 25 mg qd
Number of subjects: 543
Study 19411388 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 543
Study 19411388 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxcinod 750 mg bid
Number of subjects: 543
Study 17999010 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic ankle-foot orthoses
Number of subjects: 6
Study 17999010 — intervention group
Group type: COMPARATOR
Intervention: Typically developing children (Control)
Number of subjects: 6
Study 14693981 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (200 mg for 12 weeks)
Number of subjects: 24
Study 14693981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12351253 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium-corrected group (n = 43)
Number of subjects: 85
Study 12351253 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 42)
Number of subjects: 85
Study 9852438 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue filter treatment (flash stimulation with a blue filter during occlusion of the better eye for one hour daily)
Number of subjects: 50
Study 9852438 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue filter treatment
Number of subjects: 50
Study 9852438 — intervention group
Group type: COMPARATOR
Intervention: Classical treatment (full time total occlusion by patch)
Number of subjects: 50
Study 7989814 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative, high-dosage antibiotic administration
Number of subjects: 30
Study 7989814 — intervention group
Group type: COMPARATOR
Intervention: Existing prophylactic regimen with longer intervals and postoperative antibiotics for 7 to 10 days
Number of subjects: 30
Study 2690788 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nifedipine 10 mg
Number of subjects: 40
Study 2690788 — intervention group
Group type: COMPARATOR
Intervention: Oral captopril 50 mg
Number of subjects: 40